Expert Interview
Discussing the potential of Vertex' VX-548 with a focus on the NEJM article "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain"
Ticker(s): VRTXInstitution: UC Davis Health Center
- Chief, Division of Pain Medicine, Clinical Professor, Division of Pain Medicine & Director, Cancer Pain Management & Supportive Care at UC Davis.
- Expertise in cancer pain management, craniofacial pain and complex regional pain syndrome.
- Research interests in health services administration, pain medicine education, responsible opioid management, targeted drug delivery, and the applied use of stem cells in the setting of intervertebral disc disease.
On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for VX-548?
Added By: c_admin Did you have a view on whether that was properly
dosed or if those levels were standard of care that people might be seeing or if
you were having to talk about it?
Was the active comparator arm representative, 5 milligrams of hydrocodone and 325 milligrams of
acetaminophen every six hours? Is that representative of what a lot of your
patients would get after a bunionectomy or abdominoplasty?
When you think about concerns and focus now on opiate addiction and
exposure of patients, is this a setting that providers like yourself are focused on
to try and limit opioids? Is that across the board that's a desire?
Would you prefer to have an oral option for these patients than an injection at the time of the procedure and just be done with it for a while?
Added By: slingshot_insightsDo you have a view on that last observation carried forward with the control arms having something of a large dropout rate?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
